Roivant stock jumps as lung drug meets mid-stage goal
Roivant Sciences’ experimental mosliciguat met the mid-stage trial’s main goal for patients with high blood pressure in the arteries of the lungs and heart, prompting a surge in its shares.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.